DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 14.5% in January

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 222,800 shares, an increase of 14.5% from the December 31st total of 194,600 shares. Based on an average daily trading volume, of 93,700 shares, the days-to-cover ratio is currently 2.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock opened at $5.76 on Monday. The company’s fifty day moving average price is $5.48 and its two-hundred day moving average price is $4.54. The firm has a market capitalization of $246.30 million, a P/E ratio of -10.29 and a beta of 1.46. DiaMedica Therapeutics has a 12 month low of $2.14 and a 12 month high of $6.41.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DMAC. Point72 Asia Singapore Pte. Ltd. purchased a new stake in DiaMedica Therapeutics during the 3rd quarter worth approximately $40,000. Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics in the third quarter worth $185,000. Finally, Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after acquiring an additional 70,070 shares in the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.